Pharming milks Ruconest-egg: $10m for Phase III milestone
This article was originally published in Scrip
Executive Summary
Pharming has received $10 million from its North American partner Santarus after hitting the milestone of meeting the primary endpoint in the pivotal Phase III trial of Ruconest (conestat alfa) for the treatment of acute hereditary angioedema (HAE).